Welcome to the Therakos Institute

At the Therakos Institute, our primary goal is to advance knowledge and understanding around Extracorporeal Photopheresis (ECP) immunomodulation. We have forged valuable partnerships with leading experts from around the world, regularly bringing our best and brightest together to provide accessible education to HCPs. Through these collaborations, we aim to build a better future for patients.

Gain online access to our live and on-demand webinars.

Sign-up to the upcoming webinars to learn more about the ECP therapy and get the opportunity to watch any past webinars you didn’t have chance to attend.

Our Educational Offer

Webinars

Up-to-date coverage of a broad range of topics related to scientific, regulatory, economic and technical aspects of ECP.

Explore Our Webinars

Symposia

Major thought leaders present on specific topics on the latest in ECP Immunomodulation – guaranteed to be both stimulating and informative.

Symposia

Ask the Expert

Private, one-to-one sessions with leading experts in their respective fields of relevance to ECP and its clinical applications.

Ask the Expert

Courses

We partner with several European centres of excellence (CoE) to provide high quality professional education to committed healthcare professionals.

Courses

Speaker meetings

The latest scientific knowledge and advancements in ECP brought to life in conversation by major thought leaders.

Speaker Meetings

Partnerships

Expanding the ECP Immunomodulation educational offering of the Therakos Institute.

Partnerships

30 years of THERAKOS ECP Immunomodulation^TM treating GvHD

Discover More

Upcoming events

Symposium

Apr 12, 2024

ISHLT 2024 Clinical Symposium: The modern role of ECP in Heart and Lung transplantation: from treatment to prevention

Prague, Czech Republic

Discover More

Symposium

Apr 16, 2024

EBMT 2024 Nurse Symposium: 30 Years of ECP – Patient-centered therapy using Therakos ECP technology, then, now and in the future

Glasgow, Scotland

Symposium

Sep 6, 2024

EBMT 9th International Transplant and Cellular Therapy Course Clinical Symposium: 30 years of treating GvHD with ECP

Barcelona, Spain

Discover More

Symposium

Sep 12, 2024

16th International Congress on Lung Transplantation Clinical Symposium: Save the date

Paris, France

Symposium

Sep 12, 2024

The Tirol Kliniken, Innsbruck, Austria

Discover More

Developing leadership in healthcare

An SDA Bocconi course. Sponsored by Mallinckrodt.

Discover more

Brilliant Speakers

Our communication course dedicated to bringing our leaders into the new era of engagement.

Discover more

Create your

account to access live webinars, member events and exclusive content.

IMPORTANT SAFETY INFORMATION FOR THE THERAKOS™ PHOTOPHERESIS PROCEDURE

Indications

The THERAKOS^TM CELLEX^TM Photopheresis System is indicated for the administration of photopheresis. Please refer to the appropriate product labelling for a complete list of warnings and precautions.

Contraindications

THERAKOS^TM Photopheresis is contraindicated in:

Patients possessing a specific history of a light sensitive disease.
Patients who cannot tolerate extracorporeal volume loss or who have white blood cell counts greater than 25,000 / mm³.
Patients who have coagulation disorders or who have previously had a splenectomy.

Warnings and Precautions

THERAKOS^TM Photopheresis treatments should always be performed in locations where standard medical emergency equipment is available. Volume replacement fluids and/or volume expanders should be readily available throughout the procedure. Safety in children has not been established.

Do not expose the device to a magnetic resonance (MR) environment. The device may present a risk of projectile injury, and thermal injury and burns may occur. The device may generate artifacts in the MR image, or may not function properly.
Thromboembolic events, including pulmonary embolism and deep vein thrombosis, have been reported in the treatment of Graft versus Host Disease (GvHD). Special attention to adequate anticoagulation is advised when treating patients with GvHD.
When prescribing and administering THERAKOS^TM Photopheresis for patients receiving concomitant therapy, exercise caution when changing treatment schedules to avoid increased disease activity that may be caused by abrupt withdrawal of previous therapy.

Adverse Events

Hypotension may occur during any treatment involving extracorporeal circulation. Closely monitor the patient during the entire treatment for hypotension.
Transient pyretic reactions, 37.7–38.9°C (100–102°F), have been observed in some patients within six to eight hours of reinfusion of the photoactivated leukocyte-enriched blood. A temporary increase in erythroderma may accompany the pyretic reaction.
Treatment frequency exceeding labelling recommendations may result in anaemia.
Venous access carries a small risk of infection and pain.

Please refer to the THERAKOS^TM CELLEX^TM Photopheresis System Operator Manual for a complete list of warnings and precautions.

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOS^TM PHOTOPHERESIS

Contraindications

Methoxsalen is contraindicated in:

Patients exhibiting idiosyncratic or hypersensitivity reactions to methoxsalen, psoralen compounds, or any of the excipients
Patients with co-existing melanoma, basal cell or squamous cell skin carcinoma
Patients who are pregnant, and sexually active men and women of childbearing potential unless adequate contraception is used during treatment
Patients with aphakia because of the significantly increased risk of retinal damage due to the absence of a lens

Warnings and Precautions

Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents.
Oral administration of methoxsalen followed by cutaneous UVA exposure (PUVA therapy) is carcinogenic.
Patients should be told emphatically to wear UVA absorbing, wrap-around sunglasses for twenty-four (24) hours after methoxsalen treatment. They should wear these glasses any time they are exposed to direct or indirect sunlight, whether they are outdoors or exposed through a window.
Safety in children has not been established.

Refer to the package insert for methoxsalen sterile solution (20 micrograms / mL) or the oral 8-methoxypsoralen dosage formulation for a list of all warnings and precautions.

Please refer to the THERAKOS^TM CELLEX^TMPhotopheresis System Operator Manual for a complete list of warnings, precautions and adverse events.

Welcome to the Therakos Institute

Gain online access to our live and on-demand webinars.

Our Educational Offer

Webinars

Symposia

Ask the Expert

Courses

Speaker meetings

Partnerships

30 years of THERAKOS ECP ImmunomodulationTM treating GvHD

Upcoming events

ISHLT 2024 Clinical Symposium: The modern role of ECP in Heart and Lung transplantation: from treatment to prevention

EBMT 2024 Nurse Symposium: 30 Years of ECP – Patient-centered therapy using Therakos ECP technology, then, now and in the future

EBMT 9th International Transplant and Cellular Therapy Course Clinical Symposium: 30 years of treating GvHD with ECP

16th International Congress on Lung Transplantation Clinical Symposium: Save the date

DGTI 2024 Clinical Symposium: Save the date

THERAKOS™ CELLEX™ Photopheresis System Operating Room Course

EORTC 2024 Clinical Symposium: Durability of Response – An important parameter in the management of CTCL

Educational Course on Treating GvHD

A–Z of Treating Patients with ECP – The Nordic Approach Operating Room Course

THERAKOS™ CELLEX™ Photopheresis System Operating Room Course

Developing leadership in healthcare

Brilliant Speakers

Welcome to the Home of ECP

You are leaving the Therakos.eu website.